29.09.2011 • News

Boston Scientific Wins 14-year NIR Stent Patent Case Against J&J

Medical devices maker Boston Scientific announced that the U.S. Court of Appeals for the Federal Circuit found that its NIR Stent did not infringe Johnson &Johnson 's Fischell patent held by its subsidiary Cordis Corp.

"We are pleased with the decision and will continue to manage our litigation risks as part of our continuing effort to reduce our exposure," said Tim Pratt, Executive Vice President, Chief Administrative Officer and General Counsel for Boston Scientific.

The Judge ruled in favor of Boston Scientific in the 1998 patent infringement suit involving Johnson & Johnson. The original suit was filed in 1997.

In October 2008, the U.S. District Court Judge had awarded Johnson & Johnson damages in the amount of $406.7 million and pre-judgment interest in the amount of $296.1 million in the case involving the patent owned by Johnson & Johnson and Boston Scientific's NIR stent product. Boston Scientific said it will appeal the judgment.

The NIR stent was developed and is manufactured by Medinol, Jerusalem, Israel. Boston Scientific has an exclusive worldwide license to market and distribute the NIR stent.

The dispute was concerning to technology for balloon-expandable stents, which help doctors treat coronary heart disease.

J&J's Cordis, which specializes in the development and manufacture of interventional vascular technology, said in June that it will discontinue its clinical development program for the Nevo Sirolimus-eluting coronary stent in order to focus on other cardiovascular therapies where significant patient need exists.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.